HLS Therapeutics Management
Management criteria checks 1/4
HLS Therapeutics' CEO is Craig Millian, appointed in May 2023, has a tenure of 1.58 years. total yearly compensation is $1.41M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth CA$48.00K. The average tenure of the management team and the board of directors is 4.1 years and 2.1 years respectively.
Key information
Craig Millian
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 26.9% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.04% |
| Management average tenure | 4.1yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Oct 26
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
Sep 28Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$22m |
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$1m | US$381k | -US$28m |
Compensation vs Market: Craig's total compensation ($USD1.41M) is above average for companies of similar size in the Canadian market ($USD164.16K).
Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.
CEO
Craig Millian (56 yo)
1.6yrs
Tenure
US$1,414,327
Compensation
Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$1.41m | 0.039% CA$ 48.0k | |
| CFO & Non-Independent Director | less than a year | US$110.39k | 0.025% CA$ 30.7k | |
| Vice President of Scientific Affairs | 10.5yrs | US$313.47k | 0.16% CA$ 190.8k | |
| Senior VP of Legal | 6.6yrs | US$418.09k | 0.0016% CA$ 1.9k | |
| Chief Commercial Officer | 1.5yrs | US$437.71k | 0.0038% CA$ 4.6k | |
| Investor Relations Officer | no data | no data | no data | |
| VP & Corporate Controller | 6.9yrs | no data | no data |
4.1yrs
Average Tenure
56yo
Average Age
Experienced Management: HLS's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$1.41m | 0.039% CA$ 48.0k | |
| CFO & Non-Independent Director | 1.5yrs | US$110.39k | 0.025% CA$ 30.7k | |
| Independent Chairman of the Board | 3.5yrs | US$248.89k | 0.31% CA$ 380.5k | |
| Independent Director | 6.8yrs | US$220.00k | no data | |
| Independent Director | 3.5yrs | US$207.50k | 0% CA$ 0 | |
| Independent Director | 2.1yrs | US$209.50k | 0.0056% CA$ 6.8k | |
| Independent Director | 1.5yrs | US$112.49k | no data |
2.1yrs
Average Tenure
56yo
Average Age
Experienced Board: HLS's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| George Ulybyshev | Clarus Securities Inc. |